Molecular Targeting Technologies, Inc (MTTI)

MTTI is a clinical stage company transforming the lives of patients burdened with severe and life-threatening diseases.

MTTI’s medicine advancing selective radiotherapeutics, EBTATE targeting neuroendocrine tumors.

MTTI’s team seasoned executives from multinational pharmaceutical companies, each with a successful track record.

As Nukleon, we serve as the exclusive distributor of MTTI in the Turkish market.

For more information, you can visit the link www.mtarget.com

Nukleon Nükleer Teknoloji Araştırma San. ve Tic. Ltd. Şti
Çifte Havuzlar Mah. Eski Londra Asfaltı Cad.
No: 151/1I/1
Yıldız Teknik Üniversitesi TEKNOPARK
34220 Esenler/İstanbul
+90 212 483 73 34
© Copyright 2024 Nukleon